NCT03040791View on ClinicalTrials.gov

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

PHASE2UnknownINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

January 1, 2022

Study Completion Date

March 1, 2022

Conditions

Prostate Cancer

Interventions

DRUG

Nivolumab

Nivolumab

Trial Locations (2)

90035000

Hospital Moinhos de Vento, Porto Alegre

01246000

Instituto do Câncer do Estado de São Paulo, São Paulo

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Hospital Moinhos de Vento

OTHER

NCT03040791 - Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) | Biotech Hunter | Biotech Hunter